Mantinderpreet Singh
Neurology · Batesville, ARNPI 1689089625
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 666 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 10.1% — the pattern of someone who eats at a lot of different presentations.
Across 666 payments — averaging $15.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Biogen$902
- SK Life Science, Inc.$716
- Amneal Pharmaceuticals LLC$664
- UCB, Inc.$639
- AbbVie$601
- plus $5K from 34 others
What the payments were for
- Speaking & faculty fees$731%
- Food & beverage$9,86799%
- Education$651%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$10,005 in reported general payments places this provider in the 75th percentile of 93 neurology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 54 | $493,241 |
| IngrezzaValbenazine Tosylate | 34 | $296,356 |
| QuliptaAtogepant | 271 | $283,627 |
| Kesimpta PenOfatumumab | 29 | $276,733 |
| BriviactBrivaracetam | 151 | $253,935 |
| Nurtec OdtRimegepant Sulfate | 188 | $248,666 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 27 | $194,772 |
| Aimovig AutoinjectorErenumab-Aooe | 209 | $160,796 |
| UbrelvyUbrogepant | 91 | $122,881 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 13 | $114,219 |
| Emgality PenGalcanezumab-Gnlm | 87 | $80,743 |
| XcopriCenobamate | 54 | $77,692 |
| AmpyraDalfampridine | 12 | $52,956 |
| RytaryCarbidopa/Levodopa | 53 | $51,884 |
| Teriflunomide | 19 | $50,392 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $323 | $493,24154 claims |
| AbbVieQulipta, Ubrelvy | $601 | $406,508362 claims |
| PfizerNurtec Odt, Octagam, Zavzpret | $360 | $395,106224 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $177 | $296,35634 claims |
| UCB, Inc.Briviact | $639 | $253,935151 claims |
| CSL BehringHizentra | $16 | $194,77227 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr, Trokendi Xr | $417 | $78,58948 claims |
| SK Life Science, Inc.Xcopri | $716 | $77,69254 claims |
| Acorda Therapeutics, IncAmpyra | $87 | $52,95612 claims |
| Amneal Pharmaceuticals LLCRytary | $664 | $51,88453 claims |
| Corium, LLCAdlarity | $41 | $10,19217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 93 neurology providers in Arkansas.
Other neurology in Batesville
- Bernice AndersonBatesville$955
- Kathryn ChenaultSherwood$532K
- Steve-Felix BelingaFort Smith$183K
- Michael MorseFayetteville$149K
- Mark PippengerNorth Little Rock$109K
- Kara WayHot Springs$72K
- Keith SchlutermanConway$67K
- Shitiz SriwastavaLittle Rock$59K
- Ronald SouthJonesboro$59K
- Elizabeth SullivanLittle Rock$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.